Protalix BioTherapeutics, Inc.
PLX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 14% | 54.8% | -44.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 53.4% | 62.5% | 19.1% | 78.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | -$0 | $0 |
| % Margin | 11.9% | 7.5% | -41% | 39.6% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | $0 | $0 | -$0 | $0 |
| Tax Expense | -$0 | $0 | -$0 | $0 |
| Net Income | $0 | $0 | -$0 | $0 |
| % Margin | 13.2% | 1% | -35.8% | 35.6% |
| EPS | 0.03 | 0.002 | -0.047 | 0.089 |
| % Growth | 1,328.6% | 104.4% | -153% | – |
| EPS Diluted | 0.03 | 0.002 | -0.047 | 0.086 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | -$0 | $0 |
| % Margin | 15.6% | 11.5% | -33.4% | 42% |